Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004-Reference-Cited by-同舟云学术

Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004

Published:2013-07-04 Issue:1 Volume:122 Page:37-43
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Creutzig Ursula¹,Zimmermann Martin¹,Bourquin Jean-Pierre²,Dworzak Michael N.³,Fleischhack Gudrun⁴,Graf Norbert⁵,Klingebiel Thomas⁶,Kremens Bernhard⁴,Lehrnbecher Thomas⁶,von Neuhoff Christine¹,Ritter Jörg⁷,Sander Annette¹,Schrauder André⁸,Stackelberg Arend von⁹,Starý Jan¹⁰,Reinhardt Dirk¹

Affiliation:

1. Pediatric Hematology/Oncology, Hannover Medical School, Hannover, Germany;

2. Pediatric Hematology/Oncology, University of Zurich, Zurich, Switzerland;

3. Department of Pediatrics, St. Anna Children’s Hospital and Children’s Cancer Research Institute, Medical University of Vienna, Vienna, Austria;

4. Department of Pediatric Hematology, Oncology, University of Essen, Essen, Germany;

5. Department of Pediatric Oncology and Hematology, Medical School, Saarland University, Homburg, Germany;

6. Pediatric Hematology, Oncology, and Hemostaseology, Children’s Hospital of the University of Frankfurt, Frankfurt/Main, Germany;

7. Department of Pediatric Hematology and Oncology, University Children’s Hospital, Münster, Germany;

8. Department of Pediatric Hematology/Oncology, University Children’s Hospital, Kiel, Germany;

9. Department of Pediatric Oncology/Hematology, Charité Universitätsmedizin Berlin, Berlin, Germany; and

10. Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Czech Pediatric Hematology Working Group, Prague, Czech Republic

Abstract

Key Points AML induction with liposomal daunorubicin (80 mg/m2 per day for 3 days) shows antileukemic activity comparable to idarubicin (12 mg/m2 per day for 3 days). Liposomal daunorubicin promises to be more active in the t(8;21) subgroup and causes less treatment-related toxicity.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/1/37/1368545/37.pdf

Reference38 articles.

1. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.;Creutzig;Leukemia,2005

2. Anthracycline dose intensification in acute myeloid leukemia.;Fernandez;N Engl J Med,2009

3. High-dose daunorubicin in older patients with acute myeloid leukemia [published correction appears in N Engl J Med 2010;362:1155].;Löwenberg;N Engl J Med,2009

4. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.;van Dalen;Cochrane Database Syst Rev,2009 7

5. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.;van Dalen;Cochrane Database Syst Rev,2010 17

Cited by 151 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gemtuzumab ozogamicin for relapsed or primary refractory acute myeloid leukemia in children—the Polish Pediatric Leukemia and Lymphoma Study Group experience;Frontiers in Immunology;2023-12-22

2. Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression;European Journal of Medical Genetics;2023-12

3. Rationale and design of the Children's Oncology Group study AAML1831 integrated cardiac substudies in pediatric acute myeloid leukemia therapy;Frontiers in Cardiovascular Medicine;2023-12-01

4. Treatment outcome and prognostic factors in relapsed pediatric acute myeloid leukemia;Blood Research;2023-11-06

5. Meta-analysis of the efficacy of titanium alloy ossicles and autologous ossicles in ossiculoplasty A survey to evaluate the efficacy of titanium alloy ossicles;2023-09-14